<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04499534</url>
  </required_header>
  <id_info>
    <org_study_id>834194</org_study_id>
    <nct_id>NCT04499534</nct_id>
  </id_info>
  <brief_title>BRCA1/2 Flu Vaccine</brief_title>
  <official_title>Influenza Vaccine Study in BRCA1 or BRCA2 Carriers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate immune function in BRCA1/2 mutation carriers without cancer, specifically to&#xD;
      determine whether immune function in healthy individuals with germline loss of function&#xD;
      BRCA1/2 mutations, impacts overall immune health and fitness.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate immune function in female BRCA1/2 mutation carriers without cancer following seasonal influenza vaccination</measure>
    <time_frame>2 years</time_frame>
    <description>Analysis of the primary objective will depend on determination of the strain-specific neutralizing antibody titer change from day 0 to the last study visit, performed as the standard assay as described by the World Health Organization (WHO).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploratory analysis- phenotypic evaluation of B cell</measure>
    <time_frame>2 years</time_frame>
    <description>Phenotypic evaluation of B and T cell responses to vaccine at each timepoint. Phenotypic analysis involves flow cytometry on peripheral blood mononuclear cells (PBMC) from all subjects (10 mL blood per subject).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory analysis - transcriptional evaluation</measure>
    <time_frame>2 years</time_frame>
    <description>Transcriptional evaluation of B and T cell responses to vaccine on day 7-10 timepoint. Transcriptional analyses including quantitative real-time PCR (RT-qPCR) and RNA sequencing (RNAseq) may be performed on a subset of the study subjects on the day 7-10 time point.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>BRCA1 Mutation</condition>
  <condition>BRCA2 Mutation</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seasonal influenza vaccine</intervention_name>
    <description>To evaluate immune function in BRCA1/2 mutation carriers without cancer following seasonal influenza vaccination</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients 25 years and older, seen at Cancer Risk Evaluation Program (CREP) in the Perelman&#xD;
        Center for Advanced Medicine with BRCA1 or BRCA2 mutation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females&#xD;
&#xD;
          -  Over age 25&#xD;
&#xD;
          -  BRCA1 or BRCA2 pathogenic or likely pathogenic mutation&#xD;
&#xD;
          -  No personal cancer history apart from non melanoma skin cancer, localized thyroid&#xD;
             cancer, in situ cancers of any type&#xD;
&#xD;
          -  Participants must sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are allergic to influenza vaccination&#xD;
&#xD;
          -  Have received influenza vaccination within the past 6 months&#xD;
&#xD;
          -  Require prednisone, methotrexate, or other immunosuppressing medications&#xD;
&#xD;
          -  Have HIV infection&#xD;
&#xD;
          -  Have a history of solid organ tumor or bone marrow transplant&#xD;
&#xD;
          -  Require combination immunotherapy;&#xD;
&#xD;
          -  Are on other studies requiring blood draws that might exceed 450 mL total during the&#xD;
             period of the influenza vaccine study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Domchek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Domchek, MD</last_name>
    <phone>215-615-3360</phone>
    <email>susan.domchek@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heather Symecko, MPH</last_name>
    <phone>215-662-2770</phone>
    <email>hsymecko@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Domchek, MD</last_name>
      <phone>215-615-3360</phone>
      <email>susan.domchek@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather Symecko, MPH</last_name>
      <phone>215-662-2770</phone>
      <email>hsymecko@pennmedicine.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Susan Domchek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mouw KW, Goldberg MS, Konstantinopoulos PA, D'Andrea AD. DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discov. 2017 Jul;7(7):675-693. doi: 10.1158/2159-8290.CD-17-0226. Epub 2017 Jun 19. Review.</citation>
    <PMID>28630051</PMID>
  </reference>
  <reference>
    <citation>Brodin P, Jojic V, Gao T, Bhattacharya S, Angel CJ, Furman D, Shen-Orr S, Dekker CL, Swan GE, Butte AJ, Maecker HT, Davis MM. Variation in the human immune system is largely driven by non-heritable influences. Cell. 2015 Jan 15;160(1-2):37-47. doi: 10.1016/j.cell.2014.12.020.</citation>
    <PMID>25594173</PMID>
  </reference>
  <reference>
    <citation>Casanova JL, Abel L, Quintana-Murci L. Immunology taught by human genetics. Cold Spring Harb Symp Quant Biol. 2013;78:157-72. doi: 10.1101/sqb.2013.78.019968. Epub 2013 Oct 3. Review.</citation>
    <PMID>24092470</PMID>
  </reference>
  <reference>
    <citation>Lucas CL, Lenardo MJ. Identifying genetic determinants of autoimmunity and immune dysregulation. Curr Opin Immunol. 2015 Dec;37:28-33. doi: 10.1016/j.coi.2015.09.001. Epub 2015 Oct 2. Review.</citation>
    <PMID>26433354</PMID>
  </reference>
  <reference>
    <citation>Mak TW, Hakem A, McPherson JP, Shehabeldin A, Zablocki E, Migon E, Duncan GS, Bouchard D, Wakeham A, Cheung A, Karaskova J, Sarosi I, Squire J, Marth J, Hakem R. Brca1 required for T cell lineage development but not TCR loci rearrangement. Nat Immunol. 2000 Jul;1(1):77-82.</citation>
    <PMID>10881179</PMID>
  </reference>
  <reference>
    <citation>Cheung AM, Hande MP, Jalali F, Tsao MS, Skinnider B, Hirao A, McPherson JP, Karaskova J, Suzuki A, Wakeham A, You-Ten A, Elia A, Squire J, Bristow R, Hakem R, Mak TW. Loss of Brca2 and p53 synergistically promotes genomic instability and deregulation of T-cell apoptosis. Cancer Res. 2002 Nov 1;62(21):6194-204.</citation>
    <PMID>12414647</PMID>
  </reference>
  <reference>
    <citation>Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza --- United States, 1976-2007. MMWR Morb Mortal Wkly Rep. 2010 Aug 27;59(33):1057-62.</citation>
    <PMID>20798667</PMID>
  </reference>
  <reference>
    <citation>Herati RS, Reuter MA, Dolfi DV, Mansfield KD, Aung H, Badwan OZ, Kurupati RK, Kannan S, Ertl H, Schmader KE, Betts MR, Canaday DH, Wherry EJ. Circulating CXCR5+PD-1+ response predicts influenza vaccine antibody responses in young adults but not elderly adults. J Immunol. 2014 Oct 1;193(7):3528-37. doi: 10.4049/jimmunol.1302503. Epub 2014 Aug 29.</citation>
    <PMID>25172499</PMID>
  </reference>
  <reference>
    <citation>Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med. 2000 Dec 4;192(11):1553-62.</citation>
    <PMID>11104798</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 16, 2020</study_first_submitted>
  <study_first_submitted_qc>July 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

